New Irritable Bowel Disease And Burn Therapies Among Those Recommended By Europe’s CHMP
This article was originally published in The Pink Sheet Daily
Executive Summary
Bayer’s aflibercept, Leo’s ingenol mebutate, Almirall’s linaclotide and a proteolytic enzyme concentrate, Teva’s NexoBrid, were given positive opinions on their marketing by CHMP on Sept. 21, with Almirall taking a different approach to linaclotide’s development than that taken in the U.S.